Livagen
Also known as: KEDA, Lys-Glu-Asp-Ala, tetrapeptide KEDA
Synthetic tetrapeptide bioregulator (cytogein)
What it is
Livagen is a short synthetic peptide studied for liver protection, anti-aging, and immune function in Russian research. It's believed to work by reactivating genes that become silenced with age through epigenetic mechanisms. No FDA-approved use; primarily studied in Russian clinical settings with limited independent replication.
The scientific side
Livagen (Lys-Glu-Asp-Ala) is a synthetic tetrapeptide bioregulator derived from the amino acid composition of liver polypeptide preparations. It acts on chromatin, inducing deheterochromatinization (decondensation) of heterochromatic regions in chromosomes of aged cells, thereby reactivating previously silenced genes. It activates ribosomal gene synthetic processes, releases genes repressed by age-related condensation of euchromatic regions, and decondenses pericentromeric structural heterochromatin of chromosomes 1 and 9. Livagen also inhibits enkephalin-degrading enzymes in human serum (IC50 ~20 µM) and does not interact with mu- or delta-opioid receptors. It demonstrates tissue-specific effects consistent with its origin from liver-derived peptide complexes, and modulates digestive enzyme activity in the gastrointestinal tract and non-digestive organs. In hepatocyte cultures, it increases the level of protein synthesis, with the greatest effect observed in cells from old animals.
Class: Synthetic tetrapeptide bioregulator (cytogein)
Administration & storage
- Administration
- Oral administration (per os) in rat studies (PMID: 16075683)In vitro application to lymphocyte and tissue cultures (PMID: 12533768167052471508525317460203)
- Storage
- No storage conditions for Livagen are described in the reviewed abstracts.
- Cautions
- No human pharmacokinetic or safety data were identified in the reviewed abstracts — clinical safety profile is unknown.,Livagen is described as a weakly hydrolyzed peptide not significantly broken down by small intestinal hydrolases in vitro; systemic absorption and metabolic fate in humans are not characterized in available literature.,All chromatin/genomic studies used in vitro lymphocyte culture models; translation to in vivo human effects has not been established in the reviewed abstracts.,Sterile technique is essential for any experimental preparation involving injectable or cell-culture applications, as a general laboratory safety principle.,Combination use with cobalt ions was studied in several in vitro experiments; cobalt ions alone caused significant increases in chromosomal aberrations in old donors — the safety of such combinations in humans is not addressed in available literature.
Legal & regulatory status
Not stated in reviewed literature — requires manual verification
Not stated in reviewed literature — requires manual verification
Not stated in reviewed literature — requires manual verification
What it's studied for
- Chromatin reactivation / anti-aging epigenetic modulation in lymphocytes of aged individuals In vitro only
- Livagen induced activation of ribosomal genes, decondensation of pericentromeric structural heterochromatin, and release of genes repressed due to age-related condensation of euchromatic regions in lymphocytes from old people. PMID 12533768 Khavinson et al., Bulletin of Experimental Biology and Medicine (2002)
- Livagen (along with Epitalon and Vilon) activated synthetic processes via deheterochromatinization of nucleolus organizer regions, induced unrolling of total heterochromatin, and released heterochromatinization-repressed genes in lymphocytes of old (75–88 yr) individuals. PMID 16705247 Lezhava et al., Georgian Medical News (2006)
- Livagen induced activation of ribosome genes, decondensation of densely packed chromatin fibrils, deheterochromatinization of facultative chromatin, and decondensation of chromosome 1 and 9 pericentromeric structural chromatin in leukocytes from subjects aged 75–88 years. PMID 15085253 Khavinson et al., Bulletin of Experimental Biology and Medicine (2004)
- Livagen induced reactivation (deheterochromatinization) of chromatin and modified heterochromatinized chromosomal regions in cultured lymphocytes of aged individuals; it decreased CoCl2-induced chromosomal aberrations in old donors. PMID 17460203 Lezhava & Jokhadze, Annals of the New York Academy of Sciences (2007)
- Livagen (Lys-Glu-Asp-Ala) induced selective deheterochromatinization of chromosome regions and activation of ribosomal gene synthetic processes in lymphocytes from individuals aged 75–88 years. PMID 37042594 Lezhava et al., Georgian Medical News (2023)
- Hepatoprotective effects (liver fibrosis, hepatitis models) Mixed
- In experimental liver pathology models (fibrosis, acute and chronic hepatitis) in animals and in vitro, KEDA (Livagen) demonstrated high hepatoprotective and immunoprotective efficiency, normalizing immune and antioxidant status and restoring liver function; maximal effects were observed in aging. PMID 32362099 Kuznik et al., Advances in Gerontology (2020)
- Livagen stimulated structural and functional homeostasis of cell populations in organotypic rat liver culture, stabilizing morphological integrity and reinforcing cellular and intracellular regeneration processes. PMID 12577697 Riadnova et al., Advances in Gerontology (2002)
- Modulation of protein synthesis in hepatocytes Animal studies only
- Livagen (Lys-Glu-Asp-Ala) increased the level of protein synthesis in monolayer hepatocyte cultures from rats of different ages; the highest effect was observed in cells from old animals, and it increased the amplitude of protein synthesis fluctuations in old rats. PMID 15926314 Brodskiy et al., Izvestiia Akademii nauk (2001)
- Modulation of digestive enzyme activity Animal studies only
- Livagen is a weakly hydrolyzed peptide not significantly hydrolyzed by small intestinal peptide hydrolases. After two weeks of oral administration in rats, digestive enzyme activity decreased in young animals and increased in old animals, approaching levels seen in young control animals. PMID 16075683 Timofeeva et al., Advances in Gerontology (2005)
- Inhibition of enkephalin-degrading enzymes / endogenous opioid system modulation In vitro only
- Livagen inhibited enkephalin-degrading enzymes from human serum in vitro, with IC50 of 20 µM (more potent than Epitalon with IC50 500 µM, and more potent than puromycin, leupeptin, and D-PAM). No interaction was observed between Livagen and mu- or delta-opioid receptors of rat brain membrane fractions. PMID 12942748 Kost et al., Izvestiia Akademii nauk (2003)
- Genomic instability correction in atherosclerosis In vitro only
- Livagen (separately and combined with cobalt ions) promoted normalization of altered genomic indicators (chromosomal aberrations, aneuploidy, polyploidy) in lymphocyte cultures from atherosclerosis patients aged 80+ and younger controls, demonstrating a protective effect on chromatin. PMID 25541832 Dzhokhadze et al., Georgian Medical News (2014)
- Genomic instability correction in hypertrophic cardiomyopathy In vitro only
- Livagen tested separately and jointly with cobalt chloride in lymphocyte cultures from HCM patients and first relatives; a protective action normalizing functional genome parameters was observed, though Epithalon showed the most effective normalization of chromosomal instability. PMID 24423684 Dzhokhadze et al., Georgian Medical News (2013)
- Combined action of Livagen and cobalt ions increased frequency of large-sized NORs and associative activity of acrocentric chromosomes in HCM patients and relatives, indicating decondensation of heterochromatinized chromatin. PMID 25341254 Georgian Medical News (2014)
- DNA damage correction in breast cancer lymphocytes In vitro only
- Livagen (with cobalt ions) had a protective effect on DNA single strand breaks, chromosomal abnormalities, and sister chromatid exchanges in lymphocyte cultures from ductal breast cancer patients. PMID 28574395 Jokhadze et al., Georgian Medical News (2017)
- Livagen (along with Epithalon) lessened the effect of heavy metals on chromosome fragile site expression in lymphocytes from individuals of different age groups; the effect was statistically reliable only for young people. PMID 18830022 Dzhokhadze et al., Georgian Medical News (2008)
- Radioprotection / radiation adaptive response correction in aged individuals In vitro only
- Corrective activity of Livagen was observed in PHA-stimulated lymphocyte cultures from 72–86 year-old individuals exposed to stimulating doses of gamma-rays (0.2 and 0.5 Gy) and subsequent copper chloride treatment. PMID 17921545 Dzhokhadze et al., Georgian Medical News (2007)
- Tissue-specific growth stimulation (liver explants) Animal studies only
- Livagen stimulated growth of liver explants in organotypic culture in a tissue-specific manner consistent with its derivation from liver-based cytomedicine peptide complexes. PMID 11713572 Khavinson, Bulletin of Experimental Biology and Medicine (2001)
- Livagen exerted tissue-specific effects in organ-typical cultures of rat tissues, stimulating liver tissue explant development in a concentration-dependent manner. PMID 12096446 Khavinson et al., Advances in Gerontology (2002)
Safety signals
- Cobalt ions (CoCl2) used in combination with Livagen in several in vitro studies caused significant increases in chromosomal aberrations in old donors compared to controls (P < 0.05); Livagen partially mitigated but did not fully eliminate this genotoxic effect. PMID 17460203
- No adverse effects of Livagen itself are explicitly reported in any reviewed abstract; however, no systematic safety or toxicology studies in humans were identified. PMID 32362099
Protocol
No community dose for Livagen on record yet.
All studies (18)
- PMID 12577697 Mixed
Hepatoprotective effects (liver fibrosis, hepatitis models) - PMID 32362099 Mixed
Hepatoprotective effects (liver fibrosis, hepatitis models) - PMID 11713572 Animal studies only
Tissue-specific growth stimulation (liver explants) - PMID 12096446 Animal studies only
Tissue-specific growth stimulation (liver explants) - PMID 12533768 In vitro only
Chromatin reactivation / anti-aging epigenetic modulation in lymphocytes of aged individuals - PMID 12942748 In vitro only
Inhibition of enkephalin-degrading enzymes / endogenous opioid system modulation - PMID 15085253 In vitro only
Chromatin reactivation / anti-aging epigenetic modulation in lymphocytes of aged individuals - PMID 15926314 Animal studies only
Modulation of protein synthesis in hepatocytes - PMID 16075683 Animal studies only
Modulation of digestive enzyme activity - PMID 16705247 In vitro only
Chromatin reactivation / anti-aging epigenetic modulation in lymphocytes of aged individuals - PMID 17460203 In vitro only
Chromatin reactivation / anti-aging epigenetic modulation in lymphocytes of aged individuals - PMID 17921545 In vitro only
Radioprotection / radiation adaptive response correction in aged individuals - PMID 18830022 In vitro only
DNA damage correction in breast cancer lymphocytes - PMID 24423684 In vitro only
Genomic instability correction in hypertrophic cardiomyopathy - PMID 25341254 In vitro only
Genomic instability correction in hypertrophic cardiomyopathy - PMID 25541832 In vitro only
Genomic instability correction in atherosclerosis - PMID 28574395 In vitro only
DNA damage correction in breast cancer lymphocytes - PMID 37042594 In vitro only
Chromatin reactivation / anti-aging epigenetic modulation in lymphocytes of aged individuals
Frequently asked
What is Livagen and what is it used for?
Livagen (also called KEDA, sequence Lys-Glu-Asp-Ala) is a synthetic tetrapeptide bioregulator derived from liver polypeptide preparations. Research has studied it primarily for its ability to reactivate (deheterochromatinize) chromatin in lymphocytes of aged individuals, hepatoprotective effects in animal models of liver disease, stimulation of protein synthesis in hepatocyte cultures, and inhibition of enkephalin-degrading enzymes in vitro. The majority of evidence comes from in vitro and animal studies; human clinical trial data are not present in the reviewed literature.
What dose of Livagen should I take?
I'm not a medical professional and can't recommend a protocol for you specifically. What research has shown: the reviewed abstracts do not report established human dosing for Livagen. One rat study administered Livagen orally for two weeks without specifying the exact dose. An in vitro inhibition study reported an IC50 of 20 µM for enkephalin-degrading enzyme inhibition. These figures cannot be extrapolated to human dosing.
How does Livagen work?
Based on the reviewed literature, Livagen has been shown to induce deheterochromatinization (decondensation) of heterochromatic chromosome regions in aged lymphocytes, reactivating previously silenced genes and activating ribosomal gene synthesis. It also inhibits enkephalin-degrading enzymes in human serum with an IC50 of ~20 µM and does not bind mu- or delta-opioid receptors. In liver cultures it stimulates structural and functional homeostasis and protein synthesis, particularly in old animals. The complete mechanism of action in humans has not been established in the reviewed abstracts.
Is Livagen safe for human use?
The reviewed abstracts do not include systematic human safety or toxicology studies for Livagen. No adverse effects of Livagen itself were explicitly reported. However, several studies combined Livagen with cobalt ions, and cobalt ions alone caused significant chromosomal aberrations in old donors in vitro. All human-related studies in the reviewed literature used in vitro lymphocyte cultures, not clinical dosing. Please consult a licensed healthcare provider before use.
Can Livagen reverse aging?
Research has shown that Livagen can induce deheterochromatinization (reactivation) of chromatin in lymphocytes from aged individuals in vitro, reversing some age-associated chromatin condensation and reactivating repressed genes. It also increased protein synthesis in old rat hepatocytes more than in young ones. However, these are in vitro and animal findings; no human clinical trials demonstrating life-extension or reversal of aging are present in the reviewed abstracts. I can't suggest treatments for medical conditions — please speak with a licensed healthcare provider.
Can I stack Livagen with other peptides or compounds?
I can't recommend combining compounds — that's a prescribing decision. Here's what has been studied individually: Several abstracts examined Livagen in combination with cobalt ions in vitro, and some studies compared it alongside other peptides like Epitalon and Vilon in the same experiments. No human safety data for combinations are available in the reviewed literature.
Where can I buy Livagen?
I don't recommend vendors or sources. Please consult a licensed provider.
Has Livagen been studied in humans?
The reviewed abstracts include studies using human lymphocyte cultures (in vitro) from aged individuals, atherosclerosis patients, breast cancer patients, and hypertrophic cardiomyopathy patients. However, no randomized controlled trials or clinical pharmacokinetic studies in living human subjects were identified in the reviewed literature. Most evidence is from in vitro cell culture or animal models.
Is Livagen approved by the FDA or other regulatory agencies?
The regulatory status of Livagen is not stated in the reviewed literature and requires manual verification with the relevant regulatory authorities (FDA, Health Canada, WADA, etc.).
Does Livagen help with liver disease?
I can't suggest treatments for medical conditions. Please speak with a licensed healthcare provider. For reference, animal and in vitro studies have shown that Livagen (KEDA) demonstrated hepatoprotective and immunoprotective effects in experimental models of liver fibrosis, acute and chronic hepatitis, normalizing immune and antioxidant status, with maximal effects observed in aging models. Livagen also stabilized morphological integrity and supported regeneration processes in organotypic rat liver cultures. These findings have not been replicated in human clinical trials in the reviewed literature.